Wechselwirkungen · Intuniv
Intuniv 1 mg prolonged-release tablets Intuniv 2 mg prolonged-release tablets Intuniv 3 mg prolonged-release tablets Intuniv 4 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-131083 · Präparat HOS-097005
When patients are taking guanfacine concomitantly with a CYP3A4 inducer, an increase in the dose of guanfacine within the recommended dose range is proposed (see section 4.2). There was a significant decrease in the rate and extent of guanfacine exposure when co-administered with rifampicin, a CYP3A4 inducer. The peak plasma concentrations (Cmax) and exposure (AUC) of guanfacine decreased by 54% and 70% respectively. Other CYP3A4 inducers may have a comparable effect, see table 3 for a list of examples of CYP3A4/5 inducers, this list is not definitive.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T16:10:00Z · SHA-256 b225f42374a72478897a7ffe5fe45a28ed820ad0d048d0ca17875afae195379b · Passage 5416149cb3f167b6ac2485044c2537ae2feaffa433fb77be9815519c7925676d · Zeichen 2351–2909 im Abschnitt